This partnership will leverage BioDuro’s expertise and Atombeat’s in silico modeling know-how to launch an AI-powered platform that allows for accelerated development of next-generation peptides.

D’Herve has succeeded Dr. Singh, bringing a wealth of industry experience to the position, having previously served in senior positions at Evonik.

Strategic early planning, optimal CDMO selection, careful scale management, and stringent quality, along with greater industry collaboration, will ensure future biomanufacturing success.

Recent fatalities in clinical trials for gene therapies have led to greater regulatory scrutiny and concerns over safety, particularly in relation to the use of viral vectors, leading industry to question whether a potential therapeutic reinvention is needed.

The companies will work together, leveraging Syntekabio’s AI prediction platform for virtual screening to uncover new, high-potential indications for MetaVia’s DA-1241 oral therapy.

Through this acquisition, ESTEVE will expand its contract development and manufacturing services for small-molecule APIs from pre-clinical through to commercial manufacturing within the U.S.

The strategic collaboration will also provide GSK with an exclusive worldwide license for Hengrui’s potential best-in-class PDE3/4 inhibitor, which is in clinical development as an add-on maintenance treatment for COPD.

Pegcetacoplan (EMPAVELI), which was shown to be safe and effective in a Phase III clinical trial, is now approved for the treatment of U.S. patients 12 years and older with C3G and primary IC-MPGN.

The strategic collaboration and license agreement is potentially worth more than USD 1 billion and offer patients less burdensome treatment regimens through sustained ocular delivery of therapies.

In efforts to position itself for long-term growth, Rocket is reducing its company headcount, undergoing a structural reorganization, and prioritizing late-stage AAV cardiovascular programs.

Through the exclusive option and license agreement, Novartis will fund Matchpoint’s research into oral covalent inhibitors and will have the option to exclusively develop and commercialize all products resulting from the collaboration.

The company’s pharmaceutical educational initiative will now include an extensive collection of assets as well as an extensive library of research, industry insights, and case studies for packaging professionals.

The site in Ridgefield, N.J., will provide Thermo with additional U.S. drug product manufacturing capacity and will allow the company to meet the growing demand from pharma and biotech customers for U.S. drug product manufacturing.

Contrasting outcomes for Roche’s investigational anti-ST2 monoclonal antibody treatment for COPD, mean the company needs to discuss the outcomes with regulatory authorities and evaluate next steps.

The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements.

While the final regulatory decision is expected in the first half of 2026, the expanded use of Arexvy, to include younger at-risk adults, could help protect more than 21 million Americans vulnerable to RSV.

Increasingly complex and diverse molecules in the development pipeline and greater demand for patient-centricity are leading to a need for developers to employ advanced formulation approaches and strategies.

The company’s research in a well-established rodent model has shown that EB-003 has potential as an effective treatment for post-traumatic stress disorder, representing an opportunity in an underserved market.

Customers in Germany, France, Benelux, Poland, and the Nordics will be able to purchase the higher bulk density excipients, which are useful for those seeking to reduce tablet size, from Brenntag.

With this latest private transaction, Bain Capital, a private investment firm, joins PCI’s investor base of Kohlberg, Mubadala, and Partners Group, which are focused on supporting the company in its growth plans.